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Abstract: There has been a growing interest in the gastrointestinal system and its significance for
autism spectrum disorder (ASD), including the significance of adopting a gluten-free and casein-free
(GFCF) diet. The objective was to investigate beneficial and safety of a GFCF diet among children with
a diagnosis of ASD. We performed a systematic literature search in Medline, Embase, Cinahl, and the
Cochrane Library up to January 2020 for existing systematic reviews and individual randomized
controlled trials (RCTs). Studies were included if they investigated a GFCF diet compared to a regular
diet in children aged 3 to 17 years diagnosed with ASD, with or without comorbidities. The quality of
the identified existing reviews was assessed using A Measurement Tool to Assess Systematic Reviews
(AMSTAR). The risk of bias in RCTs was assessed using the Cochrane Risk of Bias Tool, and overall
quality of evidence was evaluated using Grades of Recommendation, Assessment, Development,
and Evaluation (GRADE). We identified six relevant RCTs, which included 143 participants. The
results from a random effect model showed no effect of a GFCF diet on clinician-reported autism
core symptoms (standardized mean difference (SMD) −0.31 (95% Cl. −0.89, 0.27)), parent-reported
functional level (mean difference (MD) 0.61 (95% Cl −5.92, 7.14)) or behavioral difficulties (MD
0.80 (95% Cl −6.56, 10.16)). On the contrary, a GFCF diet might trigger gastrointestinal adverse
effects (relative risk (RR) 2.33 (95% Cl 0.69, 7.90)). The quality of evidence ranged from low to
very low due to serious risk of bias, serious risk of inconsistency, and serious risk of imprecision.
Clinical implications of the present findings may be careful consideration of introducing a GFCF
diet to children with ASD. However, the limitations of the current literature hinder the possibility of
drawing any solid conclusion, and more high-quality RCTs are needed. The protocol is registered at
the Danish Health Authority website.
Keywords: autism spectrum disorder; gluten-free/casein-free diet; childhood
1. Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by
qualitatively impaired behavior within the core areas of social interaction and communica-
tion as well as behavior characterized by a pattern of limited, stereotypical, and repetitive
actions and interests [1,2]. The impairments are persistent and pervasive and broadly affect
the functioning of the individual in all contexts of life. The symptoms are present early
in a child’s development but may in some cases be more distinct with time, sometimes
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as demands on the child and adolescent increases or when the learned compensatory
strategies are no longer sufficient. ASD is believed to be a lifelong disability, but the clinical
presentation and level of functioning may change over time [1,3].
As of now, there is no curative treatment for ASD, but in the last couple of decades, the
role of the gastrointestinal system in the development of ASD has been a topic of interest,
based on the finding of the high prevalence of gastrointestinal problems and disorders in
individuals with ASD [4,5]. Furthermore, children with ASD have been found to exhibit
higher levels of proinflammatory cytokines following exposure to food proteins from
gluten, casein, and soy, compared with controls [6], findings that have stimulated research
investigating the link between food allergy and ASD [7,8]. Theories of mechanisms of
action of the involvement of the immune system and the gastrointestinal system in the
development of ASD are many and include the involvement of the gut-blood-brain barrier
where by-products of the gut microbiota like lipopolysaccharides and short-chain fatty
acids have been proposed to modulate the cytokine production [9]. Also, by-products
from the microbiota have been suggested to influence the synthesis of neuropeptides like
serotonin, and peptides from gluten and casein have been hypothesized to increase the
activity of the opioid system [10]. These neuropeptides are thought to result in impairments
in social behavior and communication and thus may be involved in the pathogenesis
of ASD.
Besides being hypothesized to be involved in the development of ASD [4,11], gluten-
and casein-free diet started to be used by some families a couple of decades ago as a
treatment for symptoms of ASD as well as for gastrointestinal symptoms based on case
reports [11–18]. However, a Cochrane review from 2008 [19], based on two randomized con-
trolled trials [20,21], concluded that the evidence for the efficacy of eliminating gluten and
casein from the diet, purely based on autism as an indication, is uncertain. As research is
still needed to elucidate the pathophysiologic mechanisms behind the relationship between
ASD and gluten and casein diet, recommendations on diet restrictions are presently limited
to individuals where allergic reactions or intolerance have been detected irrespective of a
diagnosis of autism [22]. Meanwhile, research has shown that the use of complementary
and alternative therapies for children and adolescents, including gluten-free and casein-free
(GFCF) diet, are widely used in real-life settings [19], even though the treatment strategy
is resource-demanding for the child with ASD and their family. Thus, to provide clini-
cians and guideline panels as well as caregivers with an updated overview of the current
evidence from randomized controlled trials, the objective of this systematic review and
meta-analysis was to synthesize the literature on the effectiveness and side effects of a
GFCF diet compared to regular diet among children aged 3 to 17 years with a diagnosis of
ASD, with or without comorbidities in randomized trials, and to rate the certainty of the
current evidence.
2. Methods
This systematic review and meta-analysis was performed according to the principles
described in the Grades of Recommendation, Assessment, Development, and Evaluation
(GRADE) approach [23], and adheres to the Preferred Reporting Items for Systematic
Review and Meta-analysis (PRISMA) [24–26] (PRISMA checklist is provided in the Supple-
mentary Material), as well as the guidelines of the Cochrane Collaboration [27]. Moreover,
this systematic review was structured according to Population, Intervention, Comparison,
and Outcome (PICO) characterization [28]. The work serves as a part of national clinical
guidelines on the treatment of ASD among children (<18 years) published by the Danish
Health Authority in 2021. As such, the study protocol (in Danish) was pre-specified, reg-
istered, and approved by the management at the Danish Health Authority in November
2019 (available at the Danish Health Authority website: www.sst.dk).
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2.1. Search Strategy
The search was conducted throughout January 2020 (last date of search was 24 January
2020) in two steps: (1) systematic reviews, meta-analysis with a filter, (2) primary literature—
randomized controlled trials (RCTs) with a filter. The reason for the two-step approach is to
accelerate the search process and thus identify primary literature from existing high-quality
systematic reviews. The databases searched were Medline, Embase, Cinahl, and Cochrane
Library via Medline and Embase. The keywords for the search were applied as controlled
vocabulary and free text. The full electronic search strategy for all databases, including
the limits used and dates of coverage, are presented in detail in Supplementary Material:
Search description. Moreover, content experts from the guideline working group were
conferred whether any studies were missing from the search, and reference lists of included
articles and previous reviews were hand-searched for potentially relevant studies. Study
authors were not contacted to identify additional studies.
2.2. Study Selection
The studies generated from the defined search strategy on both systematic reviews and
individual RCTs were imported to RefWorks, where duplicates were removed. Hereafter
the remaining references were imported into Covidence software for literature screening
and data management. One reviewer (M.L.R) evaluated the titles and abstracts for the
articles following the pre-specified criteria. Full texts identified in the first step were
screened independently by two reviewers (M.L.R. and M.N.H.). Disagreements were
resolved through discussion. Reference lists of selected articles were also searched.
To be included in the systematic review and meta-analyses, the included studies had
to fulfill the following eligibility criteria:
2.2.1. Population
Children of 3–17 years of age diagnosed with ASD according to the diagnostic criteria
of the Diagnostic Statistical Manual (DSM) or the International Classification of Diseases
(ICD) with or without comorbidities. This age range was chosen to cover children and
adolescents with ASD from the earliest age of a valid diagnosis (3 years of age) until the
eighteenth birthday, when adolescents in Denmark come of age.
2.2.2. Intervention
Diet with the elimination of both gluten and casein. In order to be able to observe a
potential change in autistic symptoms, a sufficient period is needed for the symptoms to
diminish in severity. Regarding the length of follow-up, a minimum duration of six months





1. Core autistic symptoms, clinician-/observer-reported.
Timing and effect measures
The primary outcome was investigated at the end of treatment (minimum six months
from baseline).
In crossover trials, to limit the potential presence of carryover effects of treatment
from the first period, the initial period before crossover was used [27].
Secondary outcomes
1. Adaptive functional level in the child, clinician-reported.
2. Adaptive functional level in the child, parent-reported.
3. Core autistic symptoms, parent-reported.
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4. Gastrointestinal discomfort.
5. Behavioral difficulties, clinician-/observer-reported.
6. Behavioral difficulties, parent-reported.
7. Other side effects, such as constipation, irregular bowel, diarrhea, stomach aches,
sleep disturbances, and appetite disturbances.
8. Weight change.
9. Child quality of life, parent-reported.
10. Parental well-being.
Timing and effect measures
The secondary outcomes were investigated at the end of treatment (minimum six months
from baseline).
2.3. Study Design
RCTs, including crossover design, were considered for this review.
2.4. Report Characteristics
All years were considered, and there was no restriction on publication status, i.e.,
conference abstract was considered, if the results were not already published. Only RCTs
reported in English or in a Scandinavian language were considered.
2.5. Data Extraction of Individual Randomized Trials
Data extraction was conducted independently and in duplicate by two out of three re-
viewers (C.B.K., J.F.R., and M.N.H.) using a predefined template in Covidence software [29].
Additionally, the following information on the descriptive and quantitative characteristics
of studies were extracted: (i) characteristics of the study: authorship, year, country, setting,
sample size, design, methods, duration of follow-up, source of funding, and conflict of
interest; (ii) characteristics of the population: age, ethnicity, co-interventions, information
regarding respondent bias, or representativeness of included population; (iii) details about
the intervention; (iv) details about comparator group (e.g., placebo); (v) outcomes: as
above-mentioned.
Study authors were not contacted in relation to confirming data, no assumptions and
simplifications were placed on data, and thus, study information on data items was used
as presented by study authors.
2.6. Quality Assessment
At the study level, the quality of included systematic reviews and individual stud-
ies was assessed independently and in duplicate by two out of three reviewers (C.B.K.,
J.F.R., and M.N.H.) based on (a) A Measurement Tool to Assess Systematic Reviews (AM-
STAR) [30] and (b) the criterion provided by the Cochrane Collaboration’s tool for assessing
the risk of bias of RCTs [31]. The AMSTAR tool provides 11 quality domains, and each
domain is classified into four levels of risk of bias (yes, no, not clear, or not applicable),
with yes indicating a low risk of bias. The Cochrane Collaboration’s tool provides seven
quality domains [20]. Each domain is classified into three levels of risk of bias (low, high,
or unclear) based on specific criteria. The seven domains are as follows: sequence genera-
tion, allocation concealment, blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective outcome reporting, and other sources
of bias.
At the outcome level, we assessed the certainty in the evidence of each outcome using
the GRADE approach [23], which categorized each estimate as very low, low, moderate,
or high and is an indication of the robustness in the interpretations of the results. RCTs
started at a high certainty level and were then assessed for possible downgrading based on
the following domains: overall risk of bias, inconsistency, indirectness, imprecision, and
publication bias.
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The above-mentioned quality assessments were used in the data synthesis to address
the methodological limitations and the influence it may have on the results in terms of
certainty of the evidence.
2.7. Meta-Analysis
For all outcomes that were reported as a continuous variable, the effect size was
assessed as the mean difference (MD) (95% confidence interval (CI)) if the presented data
were reported using the same measurement scale. If different measurement scales were
used, the effect size was calculated using a standardized mean difference (SMD; 95% CI).
Dichotomous outcomes were analyzed by calculating the relative risk (RR; 95% CI). To
include studies that had zero events in both intervention and control group, a risk difference
(RD; 95% CI) was calculated as a sensitivity analysis. A random-effect model was applied
for all the meta-analyses. Statistical heterogeneity was quantified using I2 statistics [32].
Review Manager Software (version 5.3) (The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, Denmark) was used to produce the analyses and forest plots.
A priori, we planned to assess publication bias through funnel plots, but since only a
few studies were included, the power of the tests is too low to distinguish chance from real
asymmetry, and therefore these analyses were not performed [27].
3. Results
3.1. Literature Search
In the search for systematic reviews, 654 references were identified. Following the
removal of duplicates and non-relevant references, we screened 20 records at full-text level,
and finally, we identified three systematic reviews [33–35] (Figure 1).
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3.2. Description of the Primary Studies
The six studies [20,21,36–39] that met the criteria to be included in the present re-
view were all RCTs conducted between 2006 and 2019. The characteristics of the six
RCTs are summarized in Tables 1–3. Three RCTs were conducted in the United States of
America (USA) [21,36,38] and the others in Spain [39], Norway [20], and Denmark [37],
respectively (Table 1). A total of 178 children aged between 2 and 9 years participated
in the included studies. Due to few numbers of primary studies, we decided to include
studies with mean ages below 3 years (Table 2). Two RCTs were double-blinded (blind-
ing of participants (subjects and parents), personnel and of outcome assessment [21,38],
three RCTs were single-blinded (blinding of outcome assessment [36], blinding of partici-
pants [20], blinding of outcome assessment [37] and no blinding was applied in the study
by Gonzalez-Domenech et al. (2019) [39] (Table 1). Two were crossover trials (where the
initial period before crossover was used) [21,39], and the remaining four RCTs included
parallel groups [20,36–38] (Table 1).
Table 1. Study identification of the six included RCTs.
Study’s First





Elder et al., 2006 [21] Florida, USA Not reported Double-blinded,crossover RCT
Conflict of interest: Not
reported
University of Florida s
College of Nursing
Biobehavioral NINR-funded
research grant P20 NR
07791-03 and
GCRC grant M01RR00082




et al., 2019 [39]
Jaen, Granada, Malaga
and Almeria, Spain Not reported Crossover RCT
The authors declare that they
have no conflict of interest.
Johnson et al., 2011 [36] Pennsylvania, USA Not reported Single-blinded RCTwith parallel group





consulting fees for Forest,
Bristol Myer Squibband has
research funding from Forest,
Bristol Myer Squibb, Johnson
and Johnson, Neuropharm,
and Curemark.
Knivsberg et al., 2002 [20] Stavanger, Norway Not reported Single-blinded RCTwith parallel group Not reported
Navarro et al., 2015 [38] Texas, USA Not reported Double-blinded RCTwith parallel group Not reported
Whiteley et al., 2010 [37] Copenhagen, Denmark NCT00614198Registered in 2008
Single-blinded RCT
with parallel group
Conflict of interest reported.
This study was supported by
the Center for Autisme, the
Nils O. Seim Family Fund for
Medical Research, the Eric
Birger Christensen Fond, the
Norwegian Protein
Intolerance Association, and
the Robert Luff Foundation.
Abbreviations: RCT: Randomized Controllled Trial.
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Abbreviations: GFCF: Gluten- and casein-free; ECO: Ecological Communication Orientation; CARS: Childhood Autism Rating Scale; ADOS:
The Autism Diagnostic Observation Schedule; ATEC: The Autism Treatment Evaluation Checklist Scale; ABC: Aberrant Behavior Checklist;
ERC-III: Behavioral Summarized Evaluation (ERC-III) scale (Evaluation Resumé du Comportement, in French); CBCL: Child Behavior
Checklist; DIPAB: Diagnosis of Psychotic Behavior in Children (Diagnose of Psykotisk Adfærd hos Børn, in Danish); GARS: Gilliam Autism
Rating Scale; VABS: Vineland Adaptive Behavior Scale.
The interventions consisted of the elimination of gluten and casein from the diet,
which varied in duration, from four weeks to one year. In four studies [20,36,37,39], parents
received instructions on how to provide a GFCF diet to their child. In the study by Navarro
et al. (2015) [38] participants followed two weeks of a GFCF diet followed by four weeks of
a GFCF diet + supplement containing brown rice flour, whereas in the study by Elder et al.
(2006) [21] a GFCF diet was provided bi-weekly (Table 3).
The comparison groups received a regular diet in four studies [20,21,37,39], a diet
without sugar in one study [36], and a GFCF diet with a dietary supplement containing
0.5 g/kg of gluten powder and 0.5 g/kg of non-fat dried milk in another RCT [38] (Table 3).
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3.3. Synthesis of Results of Primary Studies
3.3.1. Primary Outcome: Clinician-Assessed Core Symptoms
Four studies [20,21,37,39] assessed the association between GFCF diet and clinician-
reported core symptoms of ASD, and a statistically non-significant effect was shown (SMD
of −0.31 (95% Cl. −0.89, 0.27)) (Figure 4). There was moderate heterogeneity (I2 = 54%).
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3.3.2. Secondary Outcomes
The associations between GFCF diet and adaptive functioning in the child (parent-
reported), behavioral difficulties (parent-reported) [36], weight [39], and gastrointestinal
discomfort [25,37] were each assessed by one study, respectively. Two RCTs reported on
all side effects [36,37]. Some incr as incidence in the number of people with other side
effects (RR 1.89 (95% Cl. 1.11, 3.21) an RD 0.23 (95% Cl. −0.26, 0.72)) (Figur 5A,B) with
high degree of heterogeneity (I2 = 91%), and gastrointestinal discomfort (RR 2.33 (95%
Cl. 0.69, 7.90)) (Figure 6) was reported in the GFCF treatment group. Other reported
side effects besides gastrointestinal discomfort and weight loss were waking up at night
and decreased appetite. No clinically relevant effect was seen on either parent-reported
functional level of the child (MD 0.61 (95% Cl. −5.92, 7.14)) or child’s behavioral difficulties
(MD 0.80 (95% Cl. −6.56, 10.16)) (Figures 7 and 8).
For weight change, measured as body mass index (BMI, kg/m2), there was no clinically
relevant effect (MD 0.30 (95% Cl. −1.81, 2.41)) (Figure 9).
No studies described parental-reported autism core symptoms, clinician-assessed
adaptive functioning of the child, clinician-reported child’s behavioral difficulties, quality
of life of the child, or parental well-being.
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3.4. Certainty of Evidence (GRADE)
In summary, for both the primary and secondary outcomes, the quality of evidence
ranged from low to very low due to serious risk of bias, serious risk of inconsistency, and
serious risk of imprecision. A summary of findings can be found in Table 4.
Nutrients 2021, 13, 470 13 of 18
Table 4. Summary of findings on GFCF versus usual diet.
Outcome
(Timeframe) Study Results and Measurements
Certainty of the Evidence
(Justification for Ratings)
Clinician assessed core symptoms
(Minimum 6 months)
SMD: −0.31 (CI 95% −0.89–0.27)
Based on data from 120 patients in four studies
Follow up: 3–12 months
Very low a,b,c,d
Parent assessed functional level
(Minimum 6 months)
MD: 0.61 (CI 95% −5.92–7.14)
Based on data from 55 patients in one study
Follow up: 12 months
Very low a,e
Parent assessed conduct problems
(Minimum 6 months)
MD: 1.80 (CI 95% −6.56–10.16)
Based on data from 22 patients in one study
Follow up: 3 months
Very low a,c,d
Body mass index, kg/m2
(Minimum 6 months)
MD: 0.30 (CI 95% −1.81–2.41)
Based on data from 63 patients in one study Very low
e,f
Number of persons with gastrointestinal
discomfort
(Minimum 6 months)
RR: 2.33 (CI 95% 0.69–7.90)
Based on data from 22 patients in one study
Follow up: 3 months
Very low a,c,d
Number of persons with side effects
(Minimum 6 months)
RR: 1.89 (CI 95% 1.11–3.21)
RD: 0.23 (CI 95% −0.26–0.72)
Based on data from 94 patients in two studies
Follow up: 3–12 months
Very low a,c,d
CI: confidence interval; MD: mean difference; RD: risk difference; RR: risk ratio; SMD: standardized mean differences. Very low quality: we
have very little confidence in the effect estimate. a serious risk of bias; b serious risk of inconsistency; c serious risk of indirectness; d serious
risk of imprecision; e very serious risk of imprecision; f very serious risk of bias.
The Cochrane risk-of-bias domains which presented the highest risk of bias were (1)
blinding of participants and personnel (performance bias), (2) incomplete outcome data
(attrition bias), and (3) selective reporting (reporting bias), where half or more than half
of the RCTs presented a high risk of bias. The risk of selection bias, assessed by sequence
generation and allocation concealment, was unclear in four out of the six included RCTs
(Figure 10).
The quality of the evidence for the primary outcome clinician-assessed core symptoms
was very low as two out of four studies included in this analysis had a high risk of bias
due to lack of blindness of participants and evaluators of the effect, as well as incomplete
data due to a large dropout, severe inconsistent results due to high heterogeneity and
severe non-transferability due to insufficient time frame. In addition, the few children
participating (n = 120) in the analysis resulted in a severely inaccurate effect estimate.
For the secondary outcomes other side effects and gastrointestinal discomfort, the
confidence in the estimates was very low due to a lack of blindness of participants and
evaluators, as well as incomplete data due to a large dropout rate, severe non-transferability
due to insufficient time frame, inaccurate effect estimate due to few children participating
and high heterogeneity resulting in high risk of bias. Thus, it is uncertain whether GFCF
diets increase the incidence of side effects due to the very low confidence in the estimates.
For the parent-reported functional level, there was a high risk of bias due to a lack of
blindness of participants and assessors and possible selective reporting of outcomes, as
well as inaccurate effect estimate with few (n = 55) participants from a single study [37].
For parent-reported behavioral difficulties, downgrades had to be made for the same
parameters as for the above, as well as for the risk of attrition bias. Very low confidence in
the estimate due to serious risk of bias for the secondary outcome weight change was also
present, as selection, detection, and attrition bias were high, and the effect estimate was
based on few participants (n = 20) from a single study [39].
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4. Discussion
The objective of this systematic literature review and meta-analysis was to provide
clinicians and guideline panels as well as caregivers with a special interest in this field with
an updated overview and to critically assess the evidence investigating the effect of a GFCF
diet among children aged 3 to 17 years with a diagnosis of ASD. Based on the collective
evidence from the six identified RCTs [20,21,36–39], there are no indications that following
a GFCF diet has a positive effect on core symptoms of autism, behavioral difficulties, or
adaptive functional level, and there is a high degree of uncertainty due to very low quality
of evidence.
During the search, three systematic reviews [33–35] that investigated the effect of GFCF
diet among children with ASD were identified, which included five [35], four [22,33], and
three [34] of the six RCTs [20,21,36–39] included in the present review. Previous reviews
highlighted the fact that uncontrolled trials or case reports tend to show a significant
improvement of ASD symptoms after the elimination of gluten and/or casein from the diet.
However, these studies suffered from methodological flaws such as small sample sizes,
absence of control groups, use of unstandardized outcome measures, lack of blinding, and
poor ASD diagnosis characterization [33–35].
The findings of reviews based on RCTs on this subject are consistent with our findings.
Previous evidence based on results from RCTs has shown that adherence to a GFCF
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diet was not associated with an improvement in ASD outcomes [33–35]. With respect to
the primary outcome measure defined in this review, i.e., clinician-assessed core autistic
symptoms, it is noteworthy that this outcome measure was also investigated in all but
one of the six RCTs. However, the methods used to measure core symptoms of autism
differ between studies, and the widely used diagnostic instrument in research and clinical
practice, The Autism Diagnostic Observation Schedule (ADOS) [40,41], was only used in
two of the RCTs [36,37]. However, blinding regarding the primary outcome measure has
been performed in most studies.
The present review suggests that a GFCF diet may cause some increased incidence of
gastrointestinal adverse effects, which is important to bear in mind when choosing to put a
child on a gluten- and/or casein-free diet, which is often performed by parents in the hope
of reducing or even eliminating autistic symptoms. Also, it is well-known that individuals
with ASD commonly present selective eating patterns that may worsen when introducing
a diet with subsequent risk of eating disorder and/or malnutrition [42–44].
Besides gastrointestinal side effects, it is worth noticing the risk of decreased appetite
and weight loss in addition to waking up at night when introducing a gluten- and casein-
free diet. Sleep disturbances are common in children with ASD [22], and the addition of
diet restrictions to a child with ASD may worsen sleep difficulties and subsequently worsen
the well-being of the child. The finding of a risk of weight loss is important information for
clinical practice, and the use of anthropometric growth measures (weight and height and
calculation of BMI) when evaluating the effect of diet restriction should be emphasized.
The lack of efficacy of the diet may be explained by low adherence to the diet restriction
due to severity of ASD in the child and/or parental difficulties with supplying GFCF food,
possibly due to the added burden of a strict elimination diet in addition to the often stressed
family life of having children with ASD [45,46]. Five out of six included studies monitored
adherence to diet [21,36–39], mainly relying on parental reports, which are highly subjective
to selective reporting. In two included studies [21,39], where urinary concentrations of
peptide concentrations were monitored in addition to parental monitoring of adherence
to the diet, there was no significant decrease in peptide concentrations following a GFCF
diet, suggesting either contamination or no efficacy. This warrants caution regarding the
conclusions that can be drawn from the null findings. It may be noteworthy that if strict
adherence is hard for children and families to follow, causing no effect of the elimination
diet, this could point to a potential problem of the feasibility of the diet itself.
Clinical implications of the present findings may be careful consideration of intro-
ducing a GFCF diet to families with children with ASD, unless intolerance or allergy
towards gluten and/or casein has been suspected or detected, based on standardized and
validated measures.
Clinicians may inform families of the paucity of evidence of beneficial effects, and the
increased incidence of gastrointestinal adverse effects should be taken into consideration,
as well as the overall strain on the family of the added burden of introducing an elimination
diet, which may be difficult to adhere to.
Strengths and Limitations
This systematic review and meta-analyses were performed using transparent methods
and a priori defined criteria following the guidelines of the Cochrane Collaboration and
PRISMA, including protocol registration at the Danish Health Authority (in Danish),
comprehensive search, independent and duplicate full-text study selection, data extraction,
and quality assessment. Limitations included an exclusive selection of studies published in
English and Scandinavian languages and the inclusion of RCTs, which were of generally
low quality. The authors of the included studies were not contacted for further information,
and the grey literature was not searched; thus, the results are solely based on data published
in peer-reviewed articles.
The duration of the intervention was below the pre-specified sixmonth period in half
of the included studies [21,36,38], and one [20] of the two [20,37] studies with the longest
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follow-up (12 months) reported a significant effect of following a GFCF diet on core autistic
symptoms. Therefore, the absence of effect reported in this systematic review and meta-
analysis might be owed to short intervention durations in the included studies. In addition,
all secondary outcomes were addressed by one or two studies only; therefore, caution is
required when drawing conclusions. Future research should focus on conducting large-
scale clinical trials of high-quality, following the CONSORT (Consolidated Standards of
Reporting Trials) Statement, with an adequate duration time of the GFCF diet (>6 months).
Researchers should carefully monitor participant adherence to the diet.
5. Conclusions
Based on the current evidence, there seems to be no benefit of providing a GFCF diet
to children and adolescents with ASD concerning clinician-reported autism core symptoms
or parent-reported functional level and behavioral difficulties. On the contrary, a GFCF
diet might trigger gastrointestinal adverse effects. These results are consistent with the
conclusions from previous reviews. The limitations of the current literature hinder the
possibility of drawing any solid conclusion, and more well-designed, high-quality clinical
trials of sufficient duration are required.
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